Navigation Links
Transcend tRNA from Promega

ProductsTranscend tRNA from Promega
Company Promega
Item Transcend tRNA
Price Inquire
Description The Transcend Non-Radioactive Translation Detection Systems allow non-radioactive detection of proteins synthesized in vitro. Using these systems, biotinylated lysine residues are incorporated into nascent proteins during translation, eliminating the need for labeling with [35-S]methionine or other radioactive amino acids. This biotinylated lysine is added to the translation reaction as a precharged epsilon-labeled biotinylated lysine-tRNA complex (Transcend tRNA) rather than a free amino acid. After SDS-PAGE and electroblotting, the biotinylated proteins can be visualized by binding either Streptavidin-Alkaline Phosphatase (Streptavidin-AP) or Streptavidin-Horseradish Peroxidase (Streptavidin-HRP), followed either by colorimetric or chemiluminescent detection. Typically, 0.5-5ng of protein can be detected by these methods within 3-4 hours after gel electrophoresis. This sensitivity is equivalent to that achieved with [35-S]methionine incorporation and autoradiographic detection 6-12 hours after gel electrophoresis.
Info PromegaPromega
2800 Woods Hollow Rd.
Madison, WI 53711-5399 USA
Customer Service: 800-356-9526
Tech Support: 1-800-356-9526
Fax Number: 800-356-1970
Web Site: http://www.promega.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Canine Pancreatic Microsomal Membranes from Promega
2. MagneGST™ Protein Purification System from Promega
3. TNT SP6 Coupled Reticulocyte Lysate System, Trial Size from Promega
4. AgarACE Enzyme from Promega
5. DNA Polymerase I from Promega
6. RQ1 RNase-Free DNase from Promega
7. AMV Reverse Transcriptase from Promega
8. PPase-2A from Promega
9. Recombinant RNasin® Ribonuclease Inhibitor from Promega
10. RNase ONE™ Ribonuclease from Promega
11. Klenow Fragment, Exonuclease Minus from Promega
... & visualization software. See ... samples. Combine Sequest and ... confidence. Get more detailed ... your MS/MS experiments.14 day ...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
...
Biology Products:
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Ecology drives evolution. In today,s issue of the journal ... growing evidence that the reverse is also true, and ... how environmental change affects species and vice-versa. A ... a Galpagos ground finch, Geospiza fortis. In this species, ...
... available in French . , Montreal, January 28, 2011 ... a rare form of cancer that caused a strange combination of ... his stomach and colon. His medical team was stumped and was ... family: the cause of his disease and the risk for future ...
... University of the Negev (BGU) and the PTT Chemical ... research and development collaboration agreement for commercial development of ... for the production of dihomo gamma-linolenic acid (DGLA- Omega ... Parietochloris incise. The joint research will focus on optimizing ...
Cached Biology News:Cold cases gone hot: Montreal researchers solve decades-old medical mysteries using genetics 2Ben-Gurion U. and PTT Chemical sign R&D agreement to commercialize green algae strain 2
(Date:4/16/2015)... (PRWEB) April 16, 2015 Proove ... Buzz of BIO Contest for the 2015 ... (BIO), the 2015 BIO International Convention will take place ... Pennsylvania. During the Buzz of BIO contest, industry leaders ... see present at the conference. The community voting period ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
Breaking Biology Technology:Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2